Hong Kong Stock Exchange:2197

SHANGHAI, China, March 17, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Clover Biopharmaceuticals (Clover; HKEX: 2197), please note that in the third bullet point describing preliminary data from…

中国上海, March 17, 2022 (GLOBE NEWSWIRE) -- 今天早些时候由三叶草生物制药有限公司（简称“三叶草生物”；香港联交所股票代码：02197）发布同样标题的一条新闻。 敬请注意，其中描述“其他通用加强针数据，包括奥密克戎中和抗体水平“部分的第三点中，更正后的文字是 “对基础免疫接种两剂SCB-2019 (CpG 1018/铝佐剂)的个体”，而不是之前的文字“对既往感染新冠病毒的个体”。更正后的新闻稿如下:…

CHENGDU, China, March 03, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced its…

CHENGDU, China, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that…

CHENGDU, China, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; Stock code: 2197.HK), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced…

The Phase 2 trial will evaluate SCB-2019 (CpG 1018/Alum) as a booster dose in individuals previously vaccinated with CoronaVac or recombinant Covid-19 vaccine (AstraZeneca/Fiocruz) The Phase 2 trial is an investigator initiated study,…